Xilio Therapeutics, Inc.
XLO
$0.8285
-$0.0095-1.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 25.84% | 16.29% | 28.05% | 24.04% | 21.41% |
| Total Depreciation and Amortization | -16.48% | -17.17% | -9.55% | -11.22% | -8.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.99% | -16.39% | -20.01% | 0.55% | 3.84% |
| Change in Net Operating Assets | -261.32% | -255.61% | 7,880.50% | 189.87% | -2.50% |
| Cash from Operations | -5.44% | -2.27% | 220.39% | 58.41% | 26.32% |
| Capital Expenditure | -- | -- | 93.35% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 93.35% | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 99.69% | 98.14% | -98.70% | -7,938.10% |
| Issuance of Common Stock | 15,088.89% | -50.00% | 14,231.43% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 601.96% | 99.87% | 2,120.46% | 156.52% | -7,680.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.42% | 12.31% | 323.55% | 64.78% | 19.69% |